These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 25869080)
1. Radiofluorination of PSMA-HBED via Al(18)F(2+) Chelation and Biological Evaluations In Vitro. Malik N; Baur B; Winter G; Reske SN; Beer AJ; Solbach C Mol Imaging Biol; 2015 Dec; 17(6):777-85. PubMed ID: 25869080 [TBL] [Abstract][Full Text] [Related]
2. Validation of a [Al Al-Momani E; Israel I; Samnick S Appl Radiat Isot; 2017 Dec; 130():102-108. PubMed ID: 28950199 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and pre-clinical evaluation of a new class of high-affinity Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991 [TBL] [Abstract][Full Text] [Related]
4. Optimization of Labeling PSMA Eppard E; Homann T; de la Fuente A; Essler M; Rösch F J Nucl Med; 2017 Mar; 58(3):432-437. PubMed ID: 28082433 [TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation and Pilot Clinical Study of Al Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170 [TBL] [Abstract][Full Text] [Related]
6. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Eder M; Schäfer M; Bauder-Wüst U; Hull WE; Wängler C; Mier W; Haberkorn U; Eisenhut M Bioconjug Chem; 2012 Apr; 23(4):688-97. PubMed ID: 22369515 [TBL] [Abstract][Full Text] [Related]
7. (R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors. Gourni E; Canovas C; Goncalves V; Denat F; Meyer PT; Maecke HR PLoS One; 2015; 10(12):e0145755. PubMed ID: 26700033 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of a novel urea-based Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281 [TBL] [Abstract][Full Text] [Related]
9. In Vitro and In Vivo Characterization of an Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and preclinical evaluation of an Al Boschi S; Lee JT; Beykan S; Slavik R; Wei L; Spick C; Eberlein U; Buck AK; Lodi F; Cicoria G; Czernin J; Lassmann M; Fanti S; Herrmann K Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2122-2130. PubMed ID: 27329046 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector. Läppchen T; Kiefer Y; Holland JP; Bartholomä MD Nucl Med Biol; 2018 May; 60():45-54. PubMed ID: 29571066 [TBL] [Abstract][Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
13. Automatic radiosynthesis and preclinical evaluation of Zhou W; Huang S; Jiang Y; Hu K; Wang L; Han Y; Wu H Amino Acids; 2021 Jun; 53(6):929-938. PubMed ID: 34014365 [TBL] [Abstract][Full Text] [Related]
14. Radiohybrid Ligands: A Novel Tracer Concept Exemplified by Wurzer A; Di Carlo D; Schmidt A; Beck R; Eiber M; Schwaiger M; Wester HJ J Nucl Med; 2020 May; 61(5):735-742. PubMed ID: 31862804 [TBL] [Abstract][Full Text] [Related]
15. Radiolabeling Optimization and Preclinical Evaluation of the New PSMA Imaging Agent [ Zha Z; Choi SR; Ploessl K; Alexoff D; Zhao R; Zhu L; Kung HF Bioconjug Chem; 2021 May; 32(5):1017-1026. PubMed ID: 33872489 [TBL] [Abstract][Full Text] [Related]
16. Preparation of Wang Y; Shao G; Wu J; Cui C; Zang S; Qiu F; Jia R; Wang Z; Wang F Contrast Media Mol Imaging; 2018; 2018():8046541. PubMed ID: 29853810 [TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127 [TBL] [Abstract][Full Text] [Related]
19. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer. Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024 [TBL] [Abstract][Full Text] [Related]
20. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]